Isofol Medical AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.isofol.se
Clinical Trials
22
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
A Clinical Study of Arfolitixorin in Patients With mCRC
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- Drug: arfolitixorin (ARFOX + bevacizumab)
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 60
- Registration Number
- NCT06922383
- Locations
- 🇩🇪
Charité - Universitaetsmedizin Berlin, Berlin, Germany
A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 490
- Registration Number
- NCT03750786
- Locations
- 🇺🇸
840-24 - Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸840-15 - University of Southern California, Los Angeles, California, United States
🇺🇸840-01 - HOAG Memorial Hospital, Newport Beach, California, United States
Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers
- Conditions
- Phase I Study in Healthy Volunteers to Evaluate ECG Effect
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 33
- Registration Number
- NCT03203564
- Locations
- 🇸🇪
CTC Clinical Trial Consultants, Uppsala, Sweden
A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX
- Conditions
- Osteosarcoma
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 116
- Registration Number
- NCT02383901
- Locations
- 🇭🇺
Semmelweis Egyetem II. Sz. Gyermekklinika, Budapest, Hungary
🇳🇴Oslo University Hospital, Oslo, Norway
🇵🇱Intytut Matki Dziecka Klinika Chirurgii Onkologicznej Dzieci i Młodzieży, Warszawa, Poland
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
- Conditions
- Colorectal Neoplasm
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 105
- Registration Number
- NCT02244632
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇬🇷251 General Airforce Hospital, Athens, Greece
🇬🇷Medical School University of Athens, Aretaieio Hospital, Athens, Greece
- Prev
- 1
- 2
- Next
News
Isofol Medical Advances Arfolitixorin Development with New Phase Ib/II Trial for Metastatic Colorectal Cancer
Isofol Medical has received regulatory approval to initiate a Phase Ib/II clinical trial evaluating arfolitixorin in first-line treatment of metastatic colorectal cancer at Germany's prestigious Charité Universitätsmedizin Berlin.